Valencia, CA-based radioisotope development company Nusano and Atley Solutions are collaborating to accelerate the use of astatine-211 (At-211) throughout the U.S. and Europe.
The companies announced a nonexclusive memorandum of understanding to codevelop products that support the alpha-emitting radioisotope for emerging applications in oncology therapeutics. At-211’s usage is generally limited to select geographic areas near academic and medical centers where the isotope is produced in small batches, Nusano noted.
The mutual aim of the collaboration is to jointly establish commercial supply chains that can be accessed by radiopharmaceutical drug developers for clinical trials and commercial applications, according to Nusano.
The collaboration involves Nusano’s new 170,000-square-foot radioisotope production facility in West Valley City, UT, which is expected to open in 2025. Nusano noted that Atley Solutions has produced a module that automates At-211 radiopharmaceutical manufacturing, and it also offers nonclinical radiopharmaceutical development services and At-211-related targeting.